IP Library › Granted Patent US 10,662,238
Granted Patent B2
US 10,662,238 · App. 15/982,998 · Granted May 26, 2020

Single domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use

Inventors: Karin Bok (Bethesda, MD); Lorena Laura Garaicoechea (Buenos Aires, AR); Viviana Parreno (Buenos Aires, AR); Andrea Pamela Aguilar (Buenos Aires, AR); Marina Bok (Buenos Aires, AR); Lisbeth Kim Green (Olney, MD); Stanislav Vladimirovich Sosnovtsev (North Potomac, MD)
Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; Instituto Nacional De Technologia Agropecuaria
C07K16/10G01N33/56983A61K2039/505C07K2317/22C07K2317/24C07K2317/33C07K2317/34C07K2317/565C07K2317/569C07K2317/76C07K2317/92C12N2770/16011C12N2770/16034G01N2333/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,662,238
App. No.
15/982,998
Granted
May 26, 2020
Kind
B2
Abstract

Isolated V H H monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.

Claims (80)

1. A method for treating a Norovirus infection in a subject, comprising:

administering to the subject a therapeutically effective amount of an isolated V H H monoclonal antibody or an antigen binding fragment thereof, or a nucleic acid molecule encoding the V H H or antigen binding fragment,

wherein the isolated V H H monoclonal antibody specifically binds a Norovirus polypeptide and comprises a heavy chain variable domain, wherein the heavy chain variable domain comprises a heavy chain complementarity determining region (CDR)1, an CDR2 and an CDR3, and wherein:

a) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 3, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 3, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 3;

b) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 2, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 2, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 2;

c) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 1, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 1, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 1;

d) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 4, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 4, and the a CDR3 comprises amino acids 96-109 of SEQ ID NO: 4;

e) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 5, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 5, and the CDR3 comprises amino acids 97-110 of SEQ ID NO: 5;

f) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 6, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 6, and the CDR3 comprises amino acids 97-111 of SEQ ID NO: 6;

g) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 7, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 7, and the CDR3 comprises amino acids 97-111 of SEQ ID NO: 7;

h) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 8, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 8, and the CDR3 comprises amino acids 97-111 of SEQ ID NO: 8;

i) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 9, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 9, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 9;

j) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 10, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 10, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 10;

k) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 11, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 11, and the CDR3 comprises amino acids 96-114 of SEQ ID NO: 11;

l) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 12, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 12, and the CDR3 g comprises amino acids 96-112 of SEQ ID NO: 12;

m) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 13, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 13, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 13;

n) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 14, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 14, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 14;

o) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 15, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 15, and the CDR3 comprises amino acids 97-114 of SEQ ID NO: 15;

p) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 16, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 16, and the CDR3 comprises amino acids 96-107 of SEQ ID NO: 16;

q) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 17, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 17, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 17;

r) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 18, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 18, and the CDR3 comprises amino acids 97-114 of SEQ ID NO: 18;

s) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 19, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 19, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 19;

t) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 20, the CDR2 comprises amino acids 51-57 of SEQ ID NO:20, and the CDR3 comprises amino acids 96-111 of SEQ ID NO: 20;

u) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 21, the CDR2 comprises amino acids 51-57 of SEQ ID NO:21, and the CDR3 comprises amino acids 96-102 of SEQ ID NO: 21;

v) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 22, the CDR2 comprises amino acids 51-57 of SEQ ID NO:22, and the CDR3 comprises amino acids 96-110 of SEQ ID NO: 22;

w) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 23, the CDR2 comprises amino acids 50-56 of SEQ ID NO:23, and the CDR3 comprises amino acids 95-104 of SEQ ID NO: 23;

x) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 24, the CDR2 comprises amino acids 51-57 of SEQ ID NO:24, and the CDR3 comprises amino acids 96-107 of SEQ ID NO: 24;

y) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 25, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 25, and the CDR3 comprises amino acids 100-110 of SEQ ID NO: 25;

z) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 26, the CDR2 comprises amino acids 50-57 of SEQ ID NO:26, and the CDR3 comprises amino acids 96-117 of SEQ ID NO: 26;

aa) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 27, the CDR2 comprises amino acids 51-58 of SEQ ID NO:27, and the CDR3 comprises amino acids 97-108 of SEQ ID NO: 27;

bb) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 28, the CDR2 comprises amino acids 51-57 of SEQ ID NO:28, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 28;

cc) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 29, the CDR2 comprises amino acids 51-58 of SEQ ID NO:29, and the CDR3 comprises amino acids 97-115 of SEQ ID NO: 29; or

dd) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 30, the CDR2 comprises amino acids 51-58 of SEQ ID NO:30, and the CDR3 comprises amino acids 97-121 of SEQ ID NO: 30,

thereby treating the Norovirus infection.

2. The method of claim 1 , wherein the Norovirus is Genogroup I Norovirus.

3. The method of claim 1 , wherein the Norovirus is a Genogroup II Norovirus.

4. The method of claim 1 , further comprising administering to the subject an anti-viral agent.

5. The method of claim 1 , wherein:

a) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 3, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 3, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 3, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 3;

b) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 2, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 2, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 2, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 2;

c) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 1, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 1, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 1, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 1;

d) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 4, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 4, and the CDR3 comprises amino acids 96-109 of SEQ ID NO: 4, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 4;

e) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 5, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 5, and the CDR3 comprises amino acids 97-110 of SEQ ID NO: 5, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 5;

f) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 6, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 6, and the CDR5 comprises amino acids 97-111 of SEQ ID NO: 6, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 6;

g) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 7, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 7, and the CDR3 comprises amino acids 97-111 of SEQ ID NO: 7, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 7;

h) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 8, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 8, and the CDR3 comprises amino acids 97-111 of SEQ ID NO: 8, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 8;

i) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 9, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 9, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 9, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 9;

j) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 10, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 10, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 10, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 10;

k) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 11, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 11, and the CDR3 comprises amino acids 96-114 of SEQ ID NO: 11, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 11;

l) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 12, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 12, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 12, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 12;

m) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 13, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 13, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 13, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 13;

n) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 14, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 14, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 14, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 14;

o) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 15, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 15, and the CDR3 comprises amino acids 97-114 of SEQ ID NO: 15, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 15;

p) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 16, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 16, and the CDR3 comprises amino acids 96-107 of SEQ ID NO: 16, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 16;

q) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 17, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 17, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 17, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 17;

r) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 18, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 18, and the CDR3 comprises amino acids 97-114 of SEQ ID NO: 18, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 18;

s) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 19, the CDR2 comprises amino acids 51-58 of SEQ ID NO: 19, and the CDR3 comprises amino acids 97-113 of SEQ ID NO: 19, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 19;

t) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 20, the CDR2 comprises amino acids 51-57 of SEQ ID NO:20, and the CDR3 comprises amino acids 96-111 of SEQ ID NO: 20, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 20; or

u) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 21, the CDR2 comprises amino acids 51-57 of SEQ ID NO:21, and the CDR3 comprises amino acids 96-102 of SEQ ID NO: 21, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 21.

6. The method of claim 1 , wherein:

a) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 22, the CDR2 comprises amino acids 51-57 of SEQ ID NO:22, and the CDR3 comprises amino acids 96-110 of SEQ ID NO: 22, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 22;

b) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 23, the CDR2 comprises amino acids 50-56 of SEQ ID NO:23, and the CDR3 comprises amino acids 95-104 of SEQ ID NO: 23, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 23;

c) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 24, the CDR2 comprises amino acids 51-57 of SEQ ID NO:24, and the CDR3 comprises amino acids 96-107 of SEQ ID NO: 24, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 24;

d) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 25, the CDR2 comprises amino acids 51-57 of SEQ ID NO: 25, and the CDR3 comprises amino acids 100-110 of SEQ ID NO: 25, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 25;

e) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 26, the CDR2 comprises amino acids 50-57 of SEQ ID NO:26, and the CDR3 comprises amino acids 96-117 of SEQ ID NO: 26, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 26;

f) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 27, the CDR2 comprises amino acids 51-58 of SEQ ID NO:27, and the CDR3 comprises amino acids 97-108 of SEQ ID NO: 27, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 27;

g) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 28, the CDR2 comprises amino acids 51-57 of SEQ ID NO:28, and the CDR3 comprises amino acids 96-112 of SEQ ID NO: 28, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 28;

h) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 29, the CDR2 comprises amino acids 51-58 of SEQ ID NO:29, and the CDR3 comprises amino acids 97-115 of SEQ ID NO: 29, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 29; or

i) the CDR1 comprises amino acids 26-33 of SEQ ID NO: 30, the CDR2 comprises amino acids 51-58 of SEQ ID NO:30, and the CDR3 comprises amino acids 97-121 of SEQ ID NO: 30, and wherein the heavy chain variable domain of the V H H monoclonal antibody is at least 90% identical to SEQ ID NO: 30.

7. The method of claim 5 , wherein the heavy chain variable domain comprises the amino acid sequence set for the as one of SEQ ID NOs: 1-21.

8. The method of claim 6 , wherein the heavy chain variable domain comprises the amino acid sequence set forth as one of SEQ ID NOs: 22-30.

9. The method of claim 1 , wherein the isolated V H H monoclonal antibody is administered to the subject, and wherein the antibody is an IgG.

10. The method of claim 1 , wherein the isolated V H H monoclonal antibody is administered to the subject, and wherein the antibody is humanized or chimeric.

11. The method of claim 1 , wherein the antigen binding fragment is administered to the subject.

12. The method of claim 1 , wherein the subject is human.

13. The method of claim 1 , further comprising measuring viral titer in a biological sample from the subject.

14. The method of claim 1 , wherein the subject is immunocompromised.

15. The method of claim 1 , wherein the method ameliorates one or more symptoms of the Norovirus infection.

16. The method of claim 1 , wherein the method reduces viral activity in the subject.

17. The method of claim 1 , wherein the antibody or antigen binding fragment is neutralizing.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2018
From: BOK, KARIN; GREEN, LISBETH KIM; SOSNOVTSEV, STANISLAV VLADIMIROVICH
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 045926/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2018
From: GARAICOECHEA, LAURA LAURA; PARRENO, VIVIANA; AGUILAR, ANDREA PAMELA; BOK, MARINA
To: INSTITUTO NACIONAL DE TECNOLOGIA AGROPECUARIA
Reel/Frame 045926/0317 →
Continuity (3)
Continuation 14889774
Provisional Application 61821354 · May 9, 2013
Related Publication 20180251527A1 · Sep 6, 2018